By sharing this link, I acknowledge that I have read and understand the Terms and Conditions.
RAMON ANDRADE 3DCIENCIA / SCIENCE PHOTO LIBRARY RAMON ANDRADE 3DCIENCIA / SCIENCE PHOTO LIBRARY
Dasatinib leukaemia drug binding to its target, the enzyme Bcr-Abl tyrosine kinase. This enzyme is produced by a genetic mutation, the swapping of parts of two chromosomes, leading to the formation of the oncogene (cancer-causing gene) Bcr-Abl, which produces a constantly-active version of normal Abl tyrosine kinase. This causes chronic myelogenous leukaemia (CML), a cancer of white blood cells. The drug Sprycel (Dasatinib) works by binding to the active site of the Bcr-Abl enzyme, producing a change in shape that prevents the enzyme from functioning. This causes the death of cancerous cells expressing the enzyme. Sprycel is marketed by Bristol-Myers Squibb.
Model release not required. Property release not required.
Contact us if you require the original or other formats.